{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aromatase+Inhibitors&page=8", "query": { "intervention": "Aromatase Inhibitors", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 290, "total_pages": 29, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aromatase+Inhibitors&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aromatase+Inhibitors&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T20:37:32.977Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04305496", "title": "Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced (Inoperable) or Metastatic Breast Cancer" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 818, "start_date": "2020-04-16", "completion_date": "2026-06-22", "has_results": true, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-10-12T20:37:32.977Z", "location_count": 22, "location_summary": "Gilbert, Arizona • Orange, California • San Francisco, California + 19 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04305496" }, { "nct_id": "NCT03707340", "title": "A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Hyposexual Desire Disorder" ], "interventions": [ { "name": "Flibanserin Pill", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "FEMALE", "summary": "21 Years and older · Female only" }, "enrollment_count": 43, "start_date": "2018-09-14", "completion_date": "2026-10-14", "has_results": false, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-10-12T20:37:32.977Z", "location_count": 7, "location_summary": "Norwalk, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 4 more", "locations": [ { "city": "Norwalk", "state": "Connecticut" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03707340" }, { "nct_id": "NCT00382070", "title": "Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Letrozole", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "NSABP Foundation Inc", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 3966, "start_date": "2006-08", "completion_date": "2025-04", "has_results": true, "last_update_posted_date": "2024-03-22", "last_synced_at": "2026-10-12T20:37:32.977Z", "location_count": 777, "location_summary": "Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 523 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Fairbanks", "state": "Alaska" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00382070" }, { "nct_id": "NCT02712723", "title": "Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Letrozole", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Qamar Khan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 121, "start_date": "2016-02", "completion_date": "2026-12", "has_results": true, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-10-12T20:37:32.977Z", "location_count": 13, "location_summary": "Little Rock, Arkansas • Duarte, California • Santa Ana, California + 9 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Deerfield Beach", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02712723" }, { "nct_id": "NCT06075953", "title": "DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ductal Carcinoma in Situ" ], "interventions": [ { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Anastrazole", "type": "DRUG" }, { "name": "Testosterone + Anastrazole", "type": "DRUG" }, { "name": "Elacestrant", "type": "DRUG" }, { "name": "Z-endoxifen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QuantumLeap Healthcare Collaborative", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 400, "start_date": "2024-02-17", "completion_date": "2033-11", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-12T20:37:32.977Z", "location_count": 29, "location_summary": "Berkeley, California • Duarte, California • Irvine, California + 22 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06075953" }, { "nct_id": "NCT00997373", "title": "Letrozole as a Treatment of Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Endometrial Carcinoma" ], "interventions": [ { "name": "Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "FEMALE", "summary": "40 Years and older · Female only" }, "enrollment_count": 43, "start_date": "2009-10", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-10-12T20:37:32.977Z", "location_count": 2, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00997373" }, { "nct_id": "NCT06218303", "title": "Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ductal Carcinoma in Situ" ], "interventions": [ { "name": "MUC1 Peptide Vaccine", "type": "BIOLOGICAL" }, { "name": "Hiltonol®", "type": "DRUG" }, { "name": "Aromatase Inhibitor", "type": "DRUG" }, { "name": "Selective estrogen receptor modulator (SERM)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Finn, Olivera, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 50, "start_date": "2024-02-07", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-12T20:37:32.977Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06218303" }, { "nct_id": "NCT00569543", "title": "Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Treated for Newly Diagnosed Breast Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "high performance liquid chromatography", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "mass spectrometry", "type": "OTHER" }, { "name": "medical chart review", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "FEMALE", "summary": "19 Years and older · Female only" }, "enrollment_count": 27, "start_date": "2005-05-11", "completion_date": "2012-08-02", "has_results": false, "last_update_posted_date": "2023-09-01", "last_synced_at": "2026-10-12T20:37:32.977Z", "location_count": 2, "location_summary": "Rochester, Minnesota • Omaha, Nebraska", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00569543" }, { "nct_id": "NCT01824836", "title": "A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Estrogen Receptor-positive Breast Cancer", "Musculoskeletal Complications", "Progesterone Receptor-positive Breast Cancer", "Recurrent Breast Cancer", "Stage IA Breast Cancer", "Stage IB Breast Cancer", "Stage II Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer" ], "interventions": [ { "name": "anastrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1046, "start_date": "2013-06-11", "completion_date": "2026-12", "has_results": true, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-10-12T20:37:32.977Z", "location_count": 2, "location_summary": "Boston, Massachusetts • East Orange, New Jersey", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "East Orange", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01824836" }, { "nct_id": "NCT02648477", "title": "Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor Negative", "Estrogen Receptor Positive", "HER2/Neu Negative", "Progesterone Receptor Negative", "Progesterone Receptor Positive", "Stage IV Breast Cancer", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Anastrozole", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2016-03-28", "completion_date": "2023-12-30", "has_results": true, "last_update_posted_date": "2024-03-19", "last_synced_at": "2026-10-12T20:37:32.977Z", "location_count": 6, "location_summary": "Corona, California • Duarte, California • Lancaster, California + 3 more", "locations": [ { "city": "Corona", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Rancho Cucamonga", "state": "California" }, { "city": "South Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02648477" } ] }